The intervention trial of the effect of the double induction therapy with basiliximab and rituximab on the production of donor specific antibody after kidney transprantation.

The intervention trial of the effect of the double induction therapy with basiliximab and rituximab on the production of donor specific antibody after kidney transprantation. - Double induction therapy with basiliximab and rituximab.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018625

Enrollment

100

Registered

2015-08-10

Start date

2015-08-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

ABO blood type compatibile transplant The day of transplantation,administered the rituximab 200mg/body before kidney blood flow resumes. Other immunosuppressive therapy is, Basiliximab:20mg/bod

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Renal transplant patient to be enforced in our hospital obtained the consent.

Exclusion criteria

Exclusion criteria: Patient with a history of hypersensitivity to rituximab. Patient whom doctor has determined that there is not appropriate participation in this study.

Design outcomes

Primary

Measure	Time frame
Production of donor specific antibody at two years after kidney transplantation.	—

Secondary

Measure	Time frame
Serum creatinine,eGFR,an incidence of infection,rejection and adverse events at two years after kidney transplantation.	—

Countries

Japan

Contacts

Public ContactTaihei Ito

Fujita Health University Hospital Department of Organ Transplant Surgery

i-taihei@fujita-hu.ac.jp0562-93-2380

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026